Avertix's Guardian System Confirmed as Cost-Effective for High-Risk Acute Coronary Syndrome Patients

EATONTOWN, N.J., Feb. 14, 2025 /PRNewswire/ -- Avertix Medical, Inc. ("Avertix" or the "Company"), the developer of The Guardian^® system - the world's first real-time, continuous heart attack detection and patient alerting system today announced compelling new data confirming the cost-effectiveness of its Guardian™ System in high-risk acute coronary syndrome (ACS) patients.  The study, conducted by leading researchers from Duke Clinical Research Institute and published in Future Cardiology, underscores the economic value of real-time intracardiac monitoring and alerting to heart attacks.

The analysis, leveraged data from the pivotal ALERTS clinical trial complemented by findings from relevant literature, demonstrated that The Guardian system has an incremental cost-effectiveness ratio (ICER) of $58,668 per quality adjusted life year (QALY) compared to current practice. This incremental cost per QALY falls within conventional cost-effectiveness thresholds and is similar to that found for other implantable cardiac technologies, reinforcing Guardian's economic viability in cardiac care.

"The findings from this study further validate The Guardian system as a proactive clinical option in addressing the critical unmet need for early detection and intervention in high-risk ACS patients," said Tim Moran, President and Chief Executive Officer of Avertix Medical. "This economic profile adds an important datapoint to what our physician partners already know about clinical benefits—real-time, continuous intracardiac monitoring can be a game-changer for patients at risk of recurrent cardiac events. By enabling earlier hospital arrival, even for silent heart attacks, Guardian has the potential to improve outcomes and downstream sequelae, assist in sustaining quality of life, and optimize healthcare resource utilization."

Lead author Gillian Sanders Schmidler highlighted "Reducing delay between onset of occlusion and guideline-directed medical management is a well-accepted treatment goal for high-risk ACS patients. Our analysis supports that the use of The Guardian system with these patients not only improves health outcomes but is economically attractive when compared to standard of care."

The Guardian System is the first and only FDA-approved implantable heart attack warning system, designed to detect early warning signs of cardiac events and alert patients in real-time, even in cases of silent ischemia. This study further strengthens the case for expanding Guardian's adoption among healthcare providers, payers, and policymakers, highlighting its role in reducing emergency care costs and improving long-term patient outcomes.

For more information about the Guardian System and its impact on cardiac care, visit www.avertix.com.

For a link to the full economic analysis, please visit:https://doi.org/10.1080/14796678.2025.2457831

Sanders Schmidler, G. D., John, M. S., Voigt, J. D., & Krucoff, M. W. (2025). Cost-effectiveness of continuous real-time intracardiac recurrent event detection and alerting in high-risk acute coronary syndrome patients. Future Cardiology, 1–11. 

About Avertix Medical

Avertix Medical is dedicated to transforming cardiac care through innovative real-time monitoring solutions. The company's flagship product, the Guardian System, is the first and only FDA-approved implantable heart attack warning system, designed to provide early detection and real-time alerting for high-risk cardiac patients. With a commitment to advancing patient outcomes and reducing healthcare costs, Avertix continues to lead the industry in groundbreaking cardiac innovations.

Media Contact:

Philip Tom
EVP & CFO
Avertix Medical
[email protected]

SOURCE Avertix Medical